Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP-001 in hepatic impairment
NCT06619054Phase 1Completed
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KP001 (4 cohorts), sponsored by Kaken Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at 48 hours. Started Oct 2024; status: completed.
02
Drugs
KP001
Beyond the preview
Go deeper on NCT06619054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619054.